Prisons struggling with the high cost of treating inmates with viral illnesses such as hepatitis C and HIV can turn to the 340B program for relief, but participation is often tricky.
That was the takeaway of “Demystifying 340B for Correctional Institutions” a webinar conducted Wednesday by the National Hepatitis Corrections Network and the National Virus Hepatitis Roundtable. Panelists included medical and pharmacy officials from corrections systems in Alaska, Minnesota, and Rhode Island. Jeff Davis, of counsel with the law firm of Baker Donelson in Washington, D.C., illustrated how the 340B program worked within correctional institutions.
Prisons struggling with the high cost of treating inmates with viral illnesses such as hepatitis C and HIV can turn to the 340B program for relief, but participation is often tricky.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
